BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding BioCardia, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 12 | 16 | +4 |
| Shares | 245.4K | 304.3K | +58.9K (+24.0%) |
| Value | $623.8K | $593.2K | −$30.6K (−4.9%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cetera Investment Advisers | 20,275 | $39.5K | 0.00% |
| Raymond James Financial Inc | 1,838 | $3.58K | 0.00% |
| Global Retirement Partners, LLC | 411 | $801 | 0.00% |
| JPMorgan Chase & Co | 234 | $456 | 0.00% |
Sold out (0)
Institutions that held BioCardia, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
None.